Metraipolis › archive › dc_776bbf85682c

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42639460
DOI: 10.1093/ofid/ofag168
License (as archived): solo-consultazione
Archived: 2026-11-03T10:18:00.242Z
SHA-256 of the archived text: 65258ecb3858586d3b25987a290868825914bdce83eee20b1a705ab4b59d3cf3
Stable URL of this page: https://metraipolis.com/documento/dc_776bbf85682c

How to cite

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460 — Europe PMC (en), https://europepmc.org/article/MED/42639460 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_776bbf85682c (Metraipolis archive dc_776bbf85682c, sha256 65258ecb3858586d3b25987a290868825914bdce83eee20b1a705ab4b59d3cf3)

BibTeX

@misc{dc776bbf85682c,
  title = {Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains — Europe PMC PMID:42639460},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42639460},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_776bbf85682c; sha256 65258ecb3858586d3b25987a290868825914bdce83eee20b1a705ab4b59d3cf3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42639460. Agents can read the archived copy with the MCP tool read_document.